14th April 2026
Regenity Biosciences today announced the signing of a lease on a new facility in Allendale, NJ. The announcement marks not just a physical expansion, but a reflection of the company’s accelerating momentum: Regenity products are now impacting more than 5 million patients annually, the company is actively launching new products across a growing pipeline, and its reach continues to expand into new markets globally.
Allendale has been home to Regenity for more than 11 years. The new campus — consolidating operations, supply chain, packaging, R&D, and corporate leadership — is designed to meet the demands of a business that has outgrown its current footprint and shows no signs of slowing down.
As a center of excellence in collagen-based regenerative technologies, Regenity’s Allendale campus will complement its polymer-focused facility in Groningen, Netherlands, creating a globally integrated platform purpose-built for innovation and scale.
“This facility is a direct reflection of the progress we’ve made and the scale of the opportunity ahead. Our new Allendale facility gives us the infrastructure to grow every part of our business – from innovation to supply chain and manufacturing, so the products we develop reach the patients who need them, faster and at greater scale,” said Shawn McCarthy, CEO of Regenity Biosciences.
Further details on the new facility, including capabilities, will be shared in the coming months.